Benitec Limited Enters Into Binding Agreements For Treatment Of Chronic Hepatitis B Virus (HBV) With Biomics Biotechnologies In China

Published: Sep 08, 2009

Melbourne, Sep 7, 2009 (ABN Newswire) - Benitec Limited (ASX:BLT)(PINK:BNIKF) has now entered into binding agreements with China based Biomics Biotechnologies Co. Ltd. As previously announced, the companies are collaborating on a DNA directed (ddRNAi) or vector expressed RNAi for the treatment of chronic hepatitis B virus (HBV) infection.

Back to news